We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+17.81%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.3B
AUM Growth
+$879M
Cap. Flow
+$397M
Cap. Flow %
7.5%
Top 10 Hldgs %
58.3%
Holding
63
New
4
Increased
10
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$371M
2
LEGN icon
Legend Biotech
LEGN
+$250M
3
AXSM icon
Axsome Therapeutics
AXSM
+$73.8M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$66.3M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$56.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$231M
2
BLU
BELLUS Health Inc.
BLU
+$91M
3
CLDX icon
Celldex Therapeutics
CLDX
+$62.4M
4
HLVX
HilleVax
HLVX
+$29.1M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$26.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRV icon
26
Acrivon Therapeutics
ACRV
$78.4M
$62.3M 1.18%
4,810,508
– –
ICVX
27
DELISTED
Icosavax, Inc. Common Stock
ICVX
$59.2M 1.12%
5,963,565
– –
ITOS
28
DELISTED
iTeos Therapeutics
ITOS
$58.5M 1.1%
4,417,259
– –
FDMT icon
29
4D Molecular Therapeutics
FDMT
$753M
$55.5M 1.05%
+3,069,531
New +$56.5M
MLYS icon
30
Mineralys Therapeutics
MLYS
$2.56B
$54.2M 1.02%
3,178,476
– –
ALPN
31
DELISTED
Alpine Immune Sciences Inc
ALPN
$48.2M 0.91%
4,691,178
+3,063
+0.1% +$27.6K
VRDN icon
32
Viridian Therapeutics
VRDN
$2.47B
$47.8M 0.9%
2,007,946
– –
ABOS icon
33
Acumen Pharmaceuticals
ABOS
$209M
$47M 0.89%
9,770,773
– –
ACRS icon
34
Aclaris Therapeutics
ACRS
$814M
$45.6M 0.86%
4,398,453
– –
IMGN
35
DELISTED
Immunogen Inc
IMGN
$44M 0.83%
2,329,958
-19,524,000
-89% -$231M
ELVN icon
36
Enliven Therapeutics
ELVN
$3.91B
$43.3M 0.82%
2,122,465
– –
FULC icon
37
Fulcrum Therapeutics
FULC
$288M
$38.3M 0.72%
11,609,704
– –
CLYM
38
Climb Bio
CLYM
$799M
$36.8M 0.7%
13,150,849
– –
TNYA icon
39
Tenaya Therapeutics
TNYA
$150M
$35.6M 0.67%
6,067,483
– –
ANTX icon
40
AN2 Therapeutics
ANTX
$202M
$32.1M 0.61%
3,773,517
– –
PLRX icon
41
Pliant Therapeutics
PLRX
$69.4M
$31.9M 0.6%
1,762,000
– –
EYPT icon
42
EyePoint Inc
EYPT
$316M
$29.3M 0.55%
3,370,506
– –
SPRY icon
43
ARS Pharmaceuticals
SPRY
$423M
$20.2M 0.38%
3,009,678
– –
HOWL icon
44
Werewolf Therapeutics
HOWL
$47.6M
$18.7M 0.35%
6,144,881
– –
DSGN icon
45
Design Therapeutics
DSGN
$765M
$18.7M 0.35%
2,971,231
– –
SLDB icon
46
Solid Biosciences
SLDB
$897M
$18M 0.34%
3,426,286
– –
BDTX icon
47
Black Diamond Therapeutics
BDTX
$113M
$17.8M 0.34%
3,525,754
+935,850
+36% +$1.91M
NKTX icon
48
Nkarta
NKTX
$206M
$17.1M 0.32%
7,805,129
– –
CELC icon
49
Celcuity
CELC
$4.05B
$15.4M 0.29%
1,400,001
– –
IGMS
50
DELISTED
IGM Biosciences
IGMS
$8.65M 0.16%
+937,500
New +$10.5M
1
2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, RA Capital Management held 63 positions worth $5.3B, up 20% from $4.42B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RA Capital Management deployed $397M of net new capital in Q2 2023, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was Axsome Therapeutics: 1,000,000 shares worth $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Immunogen Inc, an estimated $231M trimmed.

  • RA Capital Management's largest Q2 2023 buy was Axsome Therapeutics: 1,000,000 shares worth $71.9M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q2 2023, an estimated $371M increase.
  • RA Capital Management's biggest Q2 2023 reduction was Immunogen Inc, cutting an estimated $231M.
  • RA Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $91M.
  • RA Capital Management's ten largest holdings make up 58% of its $5.3B portfolio in Q2 2023.
  • RA Capital Management opened 4 new positions and closed 9 in Q2 2023.
  • RA Capital Management's portfolio value rose 20% quarter-over-quarter to $5.3B.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.